HC Wainwright began coverage on shares of StemlineTherapeutics (NASDAQ:STML) in a report issued on Friday. The firm issued a buy rating and a $38.00 price target on the biopharmaceutical company’s stock.
Several other equities research analysts have also commented on the company. BidaskClub lowered StemlineTherapeutics from a buy rating to a hold rating in a research note on Wednesday, January 10th. ValuEngine lowered StemlineTherapeutics from a hold rating to a sell rating in a research note on Wednesday, March 7th. Finally, Zacks Investment Research lowered StemlineTherapeutics from a hold rating to a sell rating in a research note on Thursday, February 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. StemlineTherapeutics has a consensus rating of Buy and an average price target of $31.33.
Shares of NASDAQ:STML opened at $15.10 on Friday. The stock has a market cap of $456.17, a price-to-earnings ratio of -5.14 and a beta of 0.07. StemlineTherapeutics has a 12 month low of $7.30 and a 12 month high of $18.75.
StemlineTherapeutics (NASDAQ:STML) last announced its quarterly earnings results on Friday, March 16th. The biopharmaceutical company reported ($0.93) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.26). StemlineTherapeutics had a negative return on equity of 94.70% and a negative net margin of 4,689.63%. sell-side analysts anticipate that StemlineTherapeutics will post -2.62 EPS for the current fiscal year.
In other news, insider David Gionco sold 9,183 shares of the stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $17.38, for a total value of $159,600.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Kenneth Hoberman sold 1,851 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $15.67, for a total value of $29,005.17. The disclosure for this sale can be found here. In the last quarter, insiders sold 142,378 shares of company stock valued at $2,432,553. Insiders own 16.70% of the company’s stock.
Several hedge funds have recently bought and sold shares of STML. Consonance Capital Management LP grew its stake in shares of StemlineTherapeutics by 2,216.9% in the fourth quarter. Consonance Capital Management LP now owns 2,349,792 shares of the biopharmaceutical company’s stock valued at $36,657,000 after buying an additional 2,248,372 shares in the last quarter. Lyon Street Capital LLC grew its stake in shares of StemlineTherapeutics by 53.1% in the fourth quarter. Lyon Street Capital LLC now owns 829,090 shares of the biopharmaceutical company’s stock valued at $12,934,000 after buying an additional 287,628 shares in the last quarter. Millennium Management LLC grew its stake in shares of StemlineTherapeutics by 769.8% in the fourth quarter. Millennium Management LLC now owns 290,005 shares of the biopharmaceutical company’s stock valued at $4,524,000 after buying an additional 256,665 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of StemlineTherapeutics by 82.0% in the third quarter. Dimensional Fund Advisors LP now owns 219,252 shares of the biopharmaceutical company’s stock valued at $2,434,000 after buying an additional 98,775 shares in the last quarter. Finally, BlackRock Inc. grew its stake in shares of StemlineTherapeutics by 6.3% in the fourth quarter. BlackRock Inc. now owns 1,406,181 shares of the biopharmaceutical company’s stock valued at $21,936,000 after buying an additional 83,044 shares in the last quarter. Institutional investors and hedge funds own 49.87% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/09/hc-wainwright-begins-coverage-on-stemlinetherapeutics-stml.html.
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
Receive News & Ratings for StemlineTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StemlineTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.